Moneycontrol PRO
Loans
HomeNewsBusinessIPOEmcure Pharma IPO day 2: Issue oversubscribed at 3.6x led by NIIs, retail investors

Emcure Pharma IPO day 2: Issue oversubscribed at 3.6x led by NIIs, retail investors

Brokerages have positively viewed Emcure Pharma's IPO, considering the public offer fairly priced compared to listed peers.

July 04, 2024 / 14:45 IST
On the day before Emcure Pharmaceuticals' public offer launched, the company secured Rs 582.6 crore through an anchor book

On the day before Emcure Pharmaceuticals' public offer launched, the company secured Rs 582.6 crore through an anchor book

Emcure Pharmaceuticals' public issue saw a strong start on its second day of bidding on July 4, driven by non-institutional and retail investors. The Rs 1,952.03-crore public offer was subscribed 3.6 times, with bids for 4.7 crore shares against the 1.37 crore shares on offer.

The IPO of the pharma company includes a fresh issuance of shares worth Rs 800 crore and an offer-for-sale (OFS) of 1.14 crore shares valued at Rs 1,152.03 crore by existing shareholders, including promoters Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar, and Samit Satish Mehta.

Follow our live blog for all the market updates

Non-institutional investors led the bidding, subscribing 9.57 times their allotted quota, while retail investors picked up 2 times the reserved portion. Employees of Emcure Pharmaceuticals showed significant interest, placing bids 3.2 times their allotted quota. However, the portion reserved for qualified institutional buyers (QIBs) was subscribed 0.09 times.

Brokerages have positively viewed Emcure Pharma's IPO, considering the public offer fairly priced compared to listed peers. Sixteen brokerages have recommended investors to subscribe to the issue.

Also read: SEBI's uniform charge structure: Top discount brokers might see up to 20% decline in FY25 topline

Prior to the public offer going live, Emcure Pharmaceuticals raised Rs 582.6 crore through an anchor book. Prominent global investors such as Abu Dhabi Investment Authority, Goldman Sachs, and Morgan Stanley acquired shares worth over Rs 71 crore from the anchor book.

Additionally, several mutual fund houses, including SBI, HDFC, ICICI Prudential, Whiteoak Capital, Aditya Birla Sun Life Trustee, Axis, Kotak, Nippon Life India, Mirae, Franklin India, UTI, Canara Robeco, and Motilal Oswal, participated in the anchor book.

Other notable investors included HDFC Life Insurance Company, ICICI Prudential Life Insurance Company, SBI Life Insurance Company, Amundi Funds, Neuberger Berman Emerging Markets Equity Fund, The Prudential Assurance Company, Bajaj Allianz Life Insurance Company, and Max Life Insurance Company.

The price band for the public issue is set at Rs 960-1,008 per share.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Moneycontrol News
first published: Jul 4, 2024 11:11 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347